
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-08-05-2015
- Volume 11
- Issue 8
Xcelience Makes Investment in Powdersize
Investment in Powdersize adds particle-size control solutions to Xcelience’s capabilities.
Xcelience, a contract development and manufacturing organization, announced on July 31, 2015 that it has made a structured cash investment in Powdersize, a Pennsylvania-based company specializing in milling, micronization and powder-size classification for the pharmaceutical industry. This investment was made to grow Powdersize’s business and add particle-size control solutions to Xcelience’s capabilities, the company reported in a press statement.
Reducing particle size through micronization is considered the leading technology for increasing the bioavailability of oral dosage forms when the API has solubility issues. Current industry trends increasingly demand micronization of APIs with particle sizes of 1-10µm, Xcelience reports.
Powdersize will continue with expansion plans in a recently added facility, to support the additional business expected with the integration and shared development projects.
Source:
Articles in this issue
almost 11 years ago
CDMOs Move Slowly with Expansion Plansalmost 11 years ago
Accelerating Continuous API Synthesisalmost 11 years ago
BioOutsource Opens New Facility in Glasgowalmost 11 years ago
Silicone Rubber Pieces Spur Recall of Teva Productalmost 11 years ago
Baxter Recalls IV Solution for Container and Particulate Issuesalmost 11 years ago
Indian API Manufacturer Cited for Recordkeeping Failuresalmost 11 years ago
FDA Issues Quality Metrics Draft Guidance Document for Commentalmost 11 years ago
EMA Issues Guideline on Fast Tracking Drugs for Unmet Needsalmost 11 years ago
SafeBridge Updates Potent API and Drug Manufacturer Status



